We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Renal Cell Carcinoma
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
20-30% of localized RCCs will relapse after primary therapy and the majority of relapses occur in the first 1-2 years. Therefore, with his history of papillary RCC that will be the first diagnostic consideration.
He needs full staging work up, including CT of Chest, Abdomen and Pelvis (CT CAP).
We would also get labs including LDH, serum calcium levels. Also liver function studies and urinalysis.
In the absence of symptoms a bone scan is probably not indicated, especially if alkaline phosphate comes back as normal.
Depending on the results of the CT CAP, he will need a biopsy for confirmation. If his cerebral metastasis is the only site, surgical resection would be recommended over a biopsy.
His work up is incomplete and it is premature to make any treatment decisions. But for sake of discussion, we know that papillary cancers constitute only 10-15% of all renal cancers and the data regarding management is limited. Ideally he should be enrolled in a trial. Otherwise the MSKCC prognostic factor model can be applied to see if he can get temsirolimus ( poor prognosis) or other therapy, such as everolimus (RAPTOR trial),the studies for these agents had small number of patients with papillary histology. Or sunitinib and sorafenib based on phase II data.
Temsirolimus has been associated with an increased risk of intracrebral hemorrhage in patients with CNS metastases, this may preclude the use of this agent for your patient, irrespective of risk stratification.
Manjari
Pandey
MD
Sylvia Richey MD
Aug 27, 2014
Manjari Pandey MD
Aug 27, 2014
Sylvia Richey MD
Aug 27, 2014
Manjari Pandey MD
Aug 27, 2014
Apr 30, 2024
Pending Moderator approval.